The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders
Open accessAbstract
Novel allosteric modulators of G protein-coupled receptors (GPCRs) are providing fundamental advances in the development of GPCR ligands with high subtype selectivity and novel modes of efficacy that have not been possible with traditional approaches. As new allosteric modulators are advancing as drug candidates, we are developing an increased understanding of the major advantages and broad range of activities that can be achieved with these agents through selective modulation of specific signalling pathways, differential effects on GPCR homodimers versus heterodimers, and other properties. This understanding creates exciting opportunities, as well as unique challenges, in the optimization of novel therapeutic agents for disorders of the central nervous system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease
Niswender, C. M., & Conn, P. J. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.011008.145533 · Cited by 1,892
Self-citationThe mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
Structural diversity of G protein-coupled receptors and significance for drug discovery
Lagerström, M. C., & Schiöth, H. B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2518 · Cited by 1,492
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Self-citationStructure-Function of the G Protein–Coupled Receptor Superfamily
Katritch, V., Cherezov, V., & Stevens, R. C. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032112-135923 · Cited by 1,054
G Protein-Coupled Receptor Allosterism and Complexing
Christopoulos, A., & Kenakin, T. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.323 · Cited by 931
Activation and allosteric modulation of a muscarinic acetylcholine receptor
Kruse, A. C., Ring, A. M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hübner, H., Pardon, E., Valant, C., Sexton, P. M., et al. (2013) · Nature · doi:10.1038/nature12735 · Cited by 893
Signalling bias in new drug discovery: detection, quantification and therapeutic impact
Kenakin, T., & Christopoulos, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3954 · Cited by 740
Gasparini, F., Lingenhöhl, K., Stoehr, N., Flor, P. J., Heinrich, M., Vranesic, I., Biollaz, M., Allgeier, H., Heckendorn, R., Urwyler, S., et al. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00082-9 · Cited by 725
A new benzodiazepine pharmacology
Möhler, H., Fritschy, J. M., & Rudolph, U. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.2 · Cited by 716
Allosteric Modulation of G Protein–Coupled Receptors
May, L. T., Leach, K., Sexton, P. M., & Christopoulos, A. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105159 · Cited by 695
G Protein–Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives
Ferré, S., Casadó, V., Devi, L. A., Filizola, M., Jockers, R., Lohse, M. J., Milligan, G., Pin, J.-P., & Guitart, X. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008052 · Cited by 570
Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator
Wu, H., Wang, C., Gregory, K. J., Han, G. W., Cho, H. P., Xia, Y., Niswender, C. M., Katritch, V., Meiler, J., Cherezov, V., et al. (2014) · Science · doi:10.1126/science.1249489 · Cited by 539
Self-citationMetabotropic Glutamate Receptor 5 Is a Disulfide-linked Dimer
Romano, C., Yang, W.-L., & O'Malley, K. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.45.28612 · Cited by 536
Emerging paradigms in GPCR allostery: implications for drug discovery
Wootten, D., Christopoulos, A., & Sexton, P. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4052 · Cited by 498
Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor
Bokoch, M. P., Zou, Y., Rasmussen, S. G. F., Liu, C. W., Nygaard, R., Rosenbaum, D. M., Fung, J. J., Choi, H.-J., Thian, F. S., Kobilka, T. S., et al. (2010) · Nature · doi:10.1038/nature08650 · Cited by 470
The Angiotensin II AT2 Receptor Is an AT1Receptor Antagonist
AbdAlla, S., Lother, H., Abdel-tawab, A. M., & Quitterer, U. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105253200 · Cited by 463
Allosteric Modulation of the Cannabinoid CB1 Receptor
Price, M. R., Baillie, G. L., Thomas, A., Stevenson, L. A., Easson, M., Goodwin, R., McLean, A., McIntosh, L., Goodwin, G., Walker, G., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.016162 · Cited by 443
Structure of class B GPCR corticotropin-releasing factor receptor 1
Hollenstein, K., Kean, J., Bortolato, A., Cheng, R. K. Y., Doré, A. S., Jazayeri, A., Cooke, R. M., Weir, M., & Marshall, F. H. (2013) · Nature · doi:10.1038/nature12357 · Cited by 416
G-Protein–Coupled Receptor Mas Is a Physiological Antagonist of the Angiotensin II Type 1 Receptor
Kostenis, E., Milligan, G., Christopoulos, A., Sanchez-Ferrer, C. F., Heringer-Walther, S., Sexton, P. M., Gembardt, F., Kellett, E., Martini, L., Vanderheyden, P., et al. (2005) · Circulation · doi:10.1161/01.cir.0000160867.23556.7d · Cited by 415
Lindberg, J. S., Culleton, B., Wong, G., Borah, M. F., Clark, R. V., Shapiro, W. B., Roger, S. D., Husserl, F. E., Klassen, P. S., Guo, M. D., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004060512 · Cited by 413
Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs
Dror, R. O., Green, H. F., Valant, C., Borhani, D. W., Valcourt, J. R., Pan, A. C., Arlow, D. H., Canals, M., Lane, J. R., Rahmani, R., et al. (2013) · Nature · doi:10.1038/nature12595 · Cited by 411
Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain
Doré, A. S., Okrasa, K., Patel, J. C., Serrano-Vega, M., Bennett, K., Cooke, R. M., Errey, J. C., Jazayeri, A., Khan, S., Tehan, B., et al. (2014) · Nature · doi:10.1038/nature13396 · Cited by 410
Huber, K. M., Roder, J. C., & Bear, M. F. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.86.1.321 · Cited by 390
Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology
Leach, K., Sexton, P. M., & Christopoulos, A. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.004 · Cited by 363
Litschig, S., Gasparini, F., Rueegg, D., Stoehr, N., Flor, P. J., Vranesic, I., Prézeau, L., Pin, J.-P., Thomsen, C., & Kuhn, R. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12169-4 · Cited by 344
Levoye, A., Dam, J., Ayoub, M. A., Guillaume, J., Couturier, C., Delagrange, P., & Jockers, R. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601193 · Cited by 334
Doumazane, E., Scholler, P., Zwier, J. M., Trinquet, E., Rondard, P., & Pin, J. (2011) · The FASEB Journal · doi:10.1096/fj.10-163147 · Cited by 324
Ayoub, M. A., Couturier, C., Lucas-Meunier, E., Angers, S., Fossier, P., Bouvier, M., & Jockers, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200729200 · Cited by 322
Sur, C., Mallorga, P. J., Wittmann, M., Jacobson, M. A., Pascarella, D., Williams, J. B., Brandish, P. E., Pettibone, D. J., Scolnick, E. M., & Conn, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835612100 · Cited by 294
Self-citationMa, L., Seager, M. A., Wittmann, M., Jacobson, M., Bickel, D., Burno, M., Jones, K., Graufelds, V. K., Xu, G., Pearson, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900903106 · Cited by 285
Self-citationDrugs for Allosteric Sites on Receptors
Wenthur, C. J., Gentry, P. R., Mathews, T. P., & Lindsley, C. W. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134525 · Cited by 273
Self-citationDimers and beyond: The functional puzzles of class C GPCRs
Kniazeff, J., Prézeau, L., Rondard, P., Pin, J.-P., & Goudet, C. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.006 · Cited by 251
Jones, C. K., Brady, A. E., Davis, A. A., Xiang, Z., Bubser, M., Tantawy, M. N., Kane, A. S., Bridges, T. M., Kennedy, J. P., Bradley, S. R., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1850-08.2008 · Cited by 247
Self-citationMarino, M. J., Williams, D. L., O'Brien, J. A., Valenti, O., McDonald, T. P., Clements, M. K., Wang, R., DiLella, A. G., Hess, J. F., Kinney, G. G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835724100 · Cited by 240
Self-citationShirey, J. K., Brady, A. E., Jones, P. J., Davis, A. A., Bridges, T. M., Kennedy, J. P., Jadhav, S. B., Menon, U. N., Xiang, Z., Watson, M. L., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3930-09.2009 · Cited by 237
Self-citationAllosteric modulation of the muscarinic M 4 receptor as an approach to treating schizophrenia
Chan, W. Y., McKinzie, D. L., Bose, S., Mitchell, S. N., Witkin, J. M., Thompson, R. C., Christopoulos, A., Lazareno, S., Birdsall, N. J. M., Bymaster, F. P., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800567105 · Cited by 235
Melancon, B. J., Hopkins, C. R., Wood, M. R., Emmitte, K. A., Niswender, C. M., Christopoulos, A., Conn, P. J., & Lindsley, C. W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201139r · Cited by 226
Self-citationDevelopment of allosteric modulators of GPCRs for treatment of CNS disorders
Nickols, H. H., & Conn, P. J. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.013 · Cited by 226
Self-citationA Family of Highly Selective Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5
O’Brien, J. A., Lemaire, W., Chen, T.-B., Chang, R. S. L., Jacobson, M. A., Ha, S. N., Lindsley, C. W., Schaffhauser, H. J., Sur, C., Pettibone, D. J., et al. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.731 · Cited by 209
Self-citationAyoub, M. A., Levoye, A., Delagrange, P., & Jockers, R. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.000398 · Cited by 207
Urwyler, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.109.002501 · Cited by 207
Ayala, J. E., Chen, Y., Banko, J. L., Sheffler, D. J., Williams, R., Telk, A. N., Watson, N. L., Xiang, Z., Zhang, Y., Jones, P. J., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.30 · Cited by 206
Self-citationBrady, A. E., Jones, C. K., Bridges, T. M., Kennedy, J. P., Thompson, A. D., Heiman, J. U., Breininger, M. L., Gentry, P. R., Yin, H., Jadhav, S. B., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140350 · Cited by 203
Self-citationDiscovery of an Ectopic Activation Site on the M1Muscarinic Receptor
Spalding, T. A., Trotter, C., Skjærbæk, N., Messier, T. L., Currier, E. A., Burstein, E. S., Li, D., Hacksell, U., & Brann, M. R. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12088-3 · Cited by 193
Varney, M. A., Cosford, N. D. P., Jachec, C., Rao, S. P., Sacaan, A., Lin, F.-F., Bleicher, L., Santori, E. M., Flor, P. J., Allgeier, H., et al. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34881-5 · Cited by 192
Niswender, C. M., Johnson, K. A., Weaver, C. D., Jones, C. K., Xiang, Z., Luo, Q., Rodriguez, A. L., Marlo, J. E., de Paulis, T., Thompson, A. D., et al. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.049551 · Cited by 188
Self-citationLiu, F., Grauer, S., Kelley, C., Navarra, R., Graf, R., Zhang, G., Atkinson, P. J., Popiolek, M., Wantuch, C., Khawaja, X., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.136580 · Cited by 182
Annoura, H., Fukunaga, A., Uesugi, M., Tatsuoka, T., & Horikawa, Y. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(96)00104-7 · Cited by 180
Rodriguez, A. L., Grier, M. D., Jones, C. K., Herman, E. J., Kane, A. S., Smith, R. L., Williams, R., Zhou, Y., Marlo, J. E., Days, E. L., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.067207 · Cited by 178
Self-citationA Novel Mechanism of G Protein-coupled Receptor Functional Selectivity
Valant, C., Gregory, K. J., Hall, N. E., Scammells, P. J., Lew, M. J., Sexton, P. M., & Christopoulos, A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803801200 · Cited by 173
Positive and Negative Allosteric Modulators Promote Biased Signaling at the Calcium-Sensing Receptor
Davey, A. E., Leach, K., Valant, C., Conigrave, A. D., Sexton, P. M., & Christopoulos, A. (2012) · Endocrinology · doi:10.1210/en.2011-1426 · Cited by 167
Leach, K., Loiacono, R. E., Felder, C. C., McKinzie, D. L., Mogg, A., Shaw, D. B., Sexton, P. M., & Christopoulos, A. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.194 · Cited by 167
Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCR
Hlavackova, V., Goudet, C., Kniazeff, J., Zikova, A., Maurel, D., Vol, C., Trojanova, J., Prézeau, L., Pin, J., & Blahos, J. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600557 · Cited by 165
An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission
Shirey, J. K., Xiang, Z., Orton, D., Brady, A. E., Johnson, K. A., Williams, R., Ayala, J. E., Rodriguez, A. L., Wess, J., Weaver, D., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.2007.55 · Cited by 161
Self-citationAvlani, V. A., Gregory, K. J., Morton, C. J., Parker, M. W., Sexton, P. M., & Christopoulos, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702311200 · Cited by 160
“Molecular Switches” on mGluR Allosteric Ligands That Modulate Modes of Pharmacology
Wood, M. R., Hopkins, C. R., Brogan, J. T., Conn, P. J., & Lindsley, C. W. (2011) · Biochemistry · doi:10.1021/bi200129s · Cited by 157
Self-citationRole of metabotropic glutamate receptors in persistent forms of hippocampal plasticity and learning
Mukherjee, S., & Manahan‐Vaughan, D. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.005 · Cited by 152
Ahn, K. H., Mahmoud, M. M., & Kendall, D. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.316463 · Cited by 150
Marlo, J. E., Niswender, C. M., Days, E., Bridges, T. M., Xiang, Y., Rodriguez, A. L., Shirey-Rice, J. K., Brady, A. E., Nalywajko, T., Luo, Q., et al. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.052886 · Cited by 147
Self-citationExploring a role for heteromerization in GPCR signalling specificity
Rozenfeld, R., & Devi, L. A. (2010) · Biochemical Journal · doi:10.1042/bj20100458 · Cited by 144
Shen, Y., Noetzel, M. J., Johnson, K. A., Zamorano, R., Jalan‐Sakrikar, N., Gregory, K. J., Conn, P. J., & Niswender, C. M. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1129-13.2014 · Cited by 144
Self-citationMalherbe, P., Kratochwil, N. A., Knoflach, F., Zenner, M., Kew, J. N. C., Kratzeisen, C., Maerki, H. P., Adam, G., & Mutel, V. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211759200 · Cited by 138
Reichel, C. M., Schwendt, M., McGinty, J. F., Olive, M. F., & See, R. E. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.212 · Cited by 135
Valant, C., Felder, C. C., Sexton, P. M., & Christopoulos, A. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.074872 · Cited by 132
Characterization of a CNS penetrant, selective M1muscarinic receptor agonist, 77‐LH‐28‐1
Langmead, C. J., Austin, N. E., Branch, C. L., Brown, J. T., Buchanan, K. A., Davies, C. H., Forbes, I. T., Fry, V. A. H., Hagan, J. J., Herdon, H. J., et al. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.152 · Cited by 131
The role of dimerisation in the cellular trafficking of G-protein-coupled receptors
Milligan, G. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.09.010 · Cited by 130
Noetzel, M. J., Rook, J. M., Vinson, P. N., Cho, H. P., Days, E., Zhou, Y., Rodriguez, A. L., Lavreysen, H., Stauffer, S. R., Niswender, C. M., et al. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.075184 · Cited by 130
Self-citationByun, N. E., Grannan, M. D., Bubser, M., Barry, R. L., Thompson, A. D., Rosanelli, J., Gowrishankar, R., Kelm, N. D., Damon, S. M., Bridges, T. M., et al. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.2 · Cited by 126
Self-citationMelancon, B. J., Tarr, J. C., Panarese, J. D., Wood, M. R., & Lindsley, C. W. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.09.005 · Cited by 125
Self-citationGregory, K. J., Dong, E. N., Meiler, J., & Conn, P. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.007 · Cited by 123
Self-citationMa, B., Li, M., Nong, H., Shi, J.-G., Liu, G.-T., & Zhang, J.-J. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282feb0ac · Cited by 123
Rodriguez, A. L., Nong, Y., Sekaran, N. K., Alagille, D., Tamagnan, G. D., & Conn, P. J. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.016139 · Cited by 123
Self-citationFerré, S., Torvinen, M., Antoniou, K. M., Irenius, E., Civelli, O., Arenas, E., Fredholm, B. B., & Fuxé, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.8.4718 · Cited by 117
Digby, G. J., Noetzel, M. J., Bubser, M., Utley, T. J., Walker, A. G., Byun, N. E., Lebois, E. P., Xiang, Z., Sheffler, D. J., Cho, H. P., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0337-12.2012 · Cited by 113
Self-citationThe use of constitutively active GPCRs in drug discovery and functional genomics
Chalmers, D. T., & Behan, D. P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd872 · Cited by 111
Jones, C. K., Bubser, M., Thompson, A. D., Dickerson, J. W., Turle-Lorenzo, N., Amalric, M., Blobaum, A. L., Bridges, T. M., Morrison, R. D., Jadhav, S. B., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.187443 · Cited by 108
Self-citationBridges, T. M., Marlo, J. E., Niswender, C. M., Jones, C. K., Jadhav, S. B., Gentry, P. R., Plumley, H. C., Weaver, C. D., Conn, P. J., & Lindsley, C. W. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900286j · Cited by 107
Self-citationSatoh, A., Nagatomi, Y., Hirata, Y., Ito, S., Suzuki, G., Kimura, T., Maehara, S., Hikichi, H., Satow, A., Hata, M., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.07.097 · Cited by 107
Kalinichev, M., Rouillier, M., Girard, F., Royer-Urios, I., Bournique, B., Finn, T., Charvin, D., Campo, B., Poul, E. L., Mutel, V., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.200915 · Cited by 106
Bennouar, K.-E., Uberti, M. A., Melon, C., Bacolod, M. D., Jimenez, H. N., Cajina, M., Goff, L. K., Doller, D., & Gubellini, P. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.03.022 · Cited by 105
Rook, J. M., Noetzel, M. J., Pouliot, W. A., Bridges, T. M., Vinson, P. N., Cho, H. P., Zhou, Y., Gogliotti, R. D., Manka, J. T., Gregory, K. J., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.012 · Cited by 105
Self-citationLecourtier, L., Homayoun, H., Tamagnan, G. D., & Moghaddam, B. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.003 · Cited by 104
Gastambide, F., Côtel, M.-C., Gilmour, G., O’Neill, M. J., Robbins, T. W., & Tricklebank, M. D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.298 · Cited by 104
Poul, E. L., Boléa, C., Girard, F., Poli, S. M., Charvin, D., Campo, B., Chapalay, J. B., Bessif, A., Luo, B., Koser, A. J., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.196063 · Cited by 103
The Prevalence, Maintenance, and Relevance of G Protein–Coupled Receptor Oligomerization
Milligan, G. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.084780 · Cited by 103
Zhang, Y., Rodriguez, A. L., & Conn, P. J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.090308 · Cited by 102
Self-citationLebois, E. P., Bridges, T. M., Lewis, L. M., Dawson, E. S., Kane, A. S., Xiang, Z., Jadhav, S. B., Yin, H., Kennedy, J. P., Meiler, J., et al. (2009) · ACS Chemical Neuroscience · doi:10.1021/cn900003h · Cited by 101
Self-citationMathiesen, J. M., Ulven, T., Martini, L., Gerlach, L. O., Heinemann, Á., & Kostenis, E. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.010520 · Cited by 100
Allosteric enhancement of metabotropic glutamate receptor 5 function promotes spatial memory
Balschun, D., Zuschratter, W., & Wetzel, W. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.06.043 · Cited by 94
Parmentier‐Batteur, S., Hutson, P. H., Menzel, K., Uslaner, J. M., Mattson, B. A., O’Brien, J. A., Magliaro, B. C., Forest, T. W., Stump, C. A., Tynebor, R. M., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.12.003 · Cited by 93
Valenti, O., Mannaioni, G., Seabrook, G. R., Conn, P. J., & Marino, M. J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.080481 · Cited by 92
Self-citationChen, Y., Nong, Y., Goudet, C., Hemstapat, R., de Paulis, T., Pin, J., & Conn, P. J. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.032425 · Cited by 90
Self-citationGregory, K. J., Noetzel, M. J., Rook, J. M., Vinson, P. N., Stauffer, S. R., Rodriguez, A. L., Emmitte, K. A., Zhou, Y., Chun, A. C., Felts, A. S., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.080531 · Cited by 90
Self-citationAllosteric Modulators for the Treatment of Schizophrenia: Targeting Glutamatergic Networks
Menniti, F. S., Lindsley, C. W., Conn, P. J., Pandit, J., Zagouras, P., & Volkmann, R. A. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313010005 · Cited by 88
Self-citationSharma, S., Rodriguez, A. L., Conn, P. J., & Lindsley, C. W. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.05.091 · Cited by 86
Self-citationNiswender, C. M., Johnson, K. A., Miller, N., Ayala, J. E., Luo, Q., Williams, R. D., Saleh, S., Orton, D., Weaver, C. D., & Conn, P. J. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.058768 · Cited by 86
Self-citationAllosteric Modulators of GABAB Receptors: Mechanism of Action and Therapeutic Perspective
Pin, J., & Prézeau, L. (2007) · Current Neuropharmacology · doi:10.2174/157015907781695919 · Cited by 84
Leach, K., Wen, A., Davey, A. E., Sexton, P. M., Conigrave, A. D., & Christopoulos, A. (2012) · Endocrinology · doi:10.1210/en.2012-1449 · Cited by 83
Archbold, J. K., Flanagan, J. U., Watkins, H. A., Gingell, J. J., & Hay, D. L. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.05.007 · Cited by 83
Functional and Pharmacological Characteristics of Metabotropic Glutamate Receptors 2/4 Heterodimers
Kammermeier, P. J. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.078501 · Cited by 77
mGlu5negative allosteric modulators: a patent review (2013 - 2016)
Emmitte, K. A. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1280466 · Cited by 77
Noetzel, M. J., Gregory, K. J., Vinson, P. N., Manka, J. T., Stauffer, S. R., Lindsley, C. W., Niswender, C. M., Xiang, Z., & Conn, P. J. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.082891 · Cited by 77
Self-citationCalcium Sensing Receptor Activators: Calcimimetics
Harrington, P. E., & Fotsch, C. H. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707782794096 · Cited by 75
Gregory, K. J., Nguyen, E. D., Reiff, S. D., Squire, E. F., Stauffer, S. R., Lindsley, C. W., Meiler, J., & Conn, P. J. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.083949 · Cited by 74
Self-citationSharma, S., Kedrowski, J., Rook, J. M., Smith, R. L., Jones, C. K., Rodriguez, A. L., Conn, P. J., & Lindsley, C. W. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900654c · Cited by 73
Self-citationChallenges in the development of mGluR5 positive allosteric modulators: The discovery of CPPHA
Zhao, Z., Wisnoski, D. D., O’Brien, J. A., Lemaire, W., Williams, D. L., Jacobson, M. A., Wittman, M., Ha, S., Schaffhauser, H., Sur, C., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.11.081 · Cited by 71
Self-citationEmerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.
Noetzel, M. J., Jones, C. K., & Conn, P. J. (2012) · PubMed · Cited by 70
Self-citationAllosteric Modulators: The New Generation of Receptor Antagonist
Kenakin, T. P. (2004) · Molecular Interventions · doi:10.1124/mi.4.4.6 · Cited by 70
Suratman, S., Leach, K., Sexton, P. M., Felder, C. C., Loiacono, R. E., & Christopoulos, A. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01184.x · Cited by 68
Hemstapat, R., de Paulis, T., Chen, Y., Brady, A. E., Grover, V. K., Alagille, D., Tamagnan, G. D., & Conn, P. J. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.021857 · Cited by 68
Self-citationAllostery in GPCRs: ‘MWC’ revisited
Canals, M., Sexton, P. M., & Christopoulos, A. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.08.005 · Cited by 65
Lavreysen, H., Langlois, X., Ahnaou, A., Drinkenburg, W. H. I. M., Riele, P. T., Biesmans, I., der Linden, I. V., Peeters, L., Megens, A. A. H. P., Wintmolders, C., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.204990 · Cited by 63
Mistry, S. N., Valant, C., Sexton, P. M., Capuano, B., Christopoulos, A., & Scammells, P. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400540b · Cited by 63
Allosteric Modulation of Metabotropic Glutamate Receptors
Sheffler, D. J., Gregory, K. J., Rook, J. M., & Conn, P. J. (2011) · Advances in pharmacology · doi:10.1016/b978-0-12-385952-5.00010-5 · Cited by 62
Self-citationParmentier‐Batteur, S., O’Brien, J. A., Doran, S. M., Nguyen, S. J., Flick, R. B., Uslaner, J. M., Chen, H., Finger, E. N., Williams, T. M., Jacobson, M. A., et al. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.11.013 · Cited by 62
mGlu5negative allosteric modulators: a patent review (2010 – 2012)
Emmitte, K. A. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.760544 · Cited by 60
Wenthur, C. J., Morrison, R. D., Felts, A. S., Smith, K. A., Engers, J. L., Byers, F. W., Daniels, J. S., Emmitte, K. A., Conn, P. J., & Lindsley, C. W. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400439t · Cited by 57
Self-citationGjoni, T., & Urwyler, S. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.008 · Cited by 57
Rocher, J., Bonnet, B., Boléa, C., Lütjens, R., Poul, E. L., Poli, S. M., Epping-Jordan, M. P., Bessis, A., Ludwig, B., & Mutel, V. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611109060680 · Cited by 54
Lundström, L., Bissantz, C., Beck, J., Wettstein, J. G., Woltering, T. J., Wichmann, J., & Gatti, S. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01409.x · Cited by 53
Schann, S., Mayer, S., Franchet, C., Frauli, M., Steinberg, E., Thomas, M., Baron, L., & Neuville, P. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101069m · Cited by 52
Lebon, G., Langmead, C. J., Tehan, B. G., & Hulme, E. C. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.050963 · Cited by 51
Sheffler, D. J., & Conn, P. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.047 · Cited by 49
Self-citationGregory, K. J., Herman, E. J., Ramsey, A. J., Hammond, A. S., Byun, N. E., Stauffer, S. R., Manka, J. T., Jadhav, S. B., Bridges, T. M., Weaver, C. D., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.206623 · Cited by 49
Self-citationOverview of Receptor Allosterism
Gregory, K. J., Sexton, P. M., & Christopoulos, A. (2010) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0121s51 · Cited by 48
Emerging opportunities for allosteric modulation of G-protein coupled receptors
Wang, C.-I. A., & Lewis, R. J. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.09.001 · Cited by 47
Functional importance of GLP-1 receptor species and expression levels in cell lines
Knudsen, L. B., Hastrup, S., Underwood, C. R., Wulff, B. S., & Fleckner, J. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2011.12.006 · Cited by 41
Assessment and Challenges of Ligand Docking into Comparative Models of G-Protein Coupled Receptors
Nguyen, E., Norn, C. H., Frimurer, T., & Meiler, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067302 · Cited by 41
Self-citationWang, X., Horswill, J. G., Whalley, B. J., & Stephens, G. J. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.068197 · Cited by 39
Potentiating mGluR5 function with a positive allosteric modulator enhances adaptive learningPreprint
Xu, J., Zhu, Y., Kraniotis, S., He, Q., Marshall, J. J., Nomura, T., Stauffer, S. R., Lindsley, C. W., Conn, P. J., & Contractor, A. (2013) · Learning & Memory · doi:10.1101/lm.031666.113 · Cited by 39
Self-citationGastambide, F., Gilmour, G., Robbins, T. W., & Tricklebank, M. D. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.039 · Cited by 36
Is There a Path Forward for mGlu2 Positive Allosteric Modulators for the Treatment of Schizophrenia?
Hopkins, C. R. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400023y · Cited by 36
Lindsley, C. W., & Hopkins, C. R. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.679437 · Cited by 36
Self-citationOrthosteric- and allosteric-induced ligand-directed trafficking at GPCRs.
Digby, G. J., Conn, P. J., & Lindsley, C. W. (2010) · PubMed · Cited by 36
Self-citationWong, R. K. S., Bianchi, R., Chuang, S.-C., & Merlin, L. R. (2005) · Epiliepsy currents/Epilepsy currents · doi:10.1111/j.1535-7597.2005.05207.x · Cited by 33
Sanger, H., Hanna, L., Colvin, E. M., Grubisha, O., Ursu, D., Heinz, B. A., Findlay, J. D., Vivier, R. G., Sher, E., Lodge, D., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.023 · Cited by 29
Hoare, S. R. J., Fleck, B. A., Gross, R. S., Crowe, P. D., Williams, J. P., & Grigoriadis, D. E. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.042978 · Cited by 29
The Concept of Allosteric Interaction and Its Consequences for the Chemistry of the Brain
Changeux, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.x113.503375 · Cited by 25
Jones, P. J., Xiang, Z., & Conn, P. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.043 · Cited by 18
Self-citation
Cited by
Current Concepts and Treatments of Schizophrenia
Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018) · Molecules · doi:10.3390/molecules23082087 · Cited by 556
GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures
Shimada, I., Ueda, T., Kofuku, Y., Eddy, M. T., & Wüthrich, K. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.180 · Cited by 279
Complex Pharmacology of Free Fatty Acid Receptors
Milligan, G., Shimpukade, B., Ulven, T., & Hudson, B. D. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00056 · Cited by 267
Novel Allosteric Modulators of G Protein-coupled Receptors
Gentry, P. R., Sexton, P. M., & Christopoulos, A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.662759 · Cited by 199
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Metadata
- Authors
- Conn, P. J., Lindsley, C. W., Meiler, J., & Niswender, C. M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-09
- Volume
- 13
- Issue
- 9
- Pages
- 692-708
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2057916169
- Cited by
- 260
- References
- 143
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.